ID   8-MG-BA
AC   CVCL_1052
SY   8MGBA
DR   CLO; CLO_0001523
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473597
DR   BioSample; SAMN10988303
DR   CCLE; 8MGBA_CENTRAL_NERVOUS_SYSTEM
DR   Cell_Model_Passport; SIDM00998
DR   ChEMBL-Cells; CHEMBL3308251
DR   ChEMBL-Targets; CHEMBL2366115
DR   Cosmic; 687562
DR   Cosmic; 1746945
DR   Cosmic; 2302327
DR   Cosmic; 2367505
DR   Cosmic-CLP; 687562
DR   DepMap; ACH-000137
DR   DSMZ; ACC-432
DR   GDSC; 687562
DR   GEO; GSM326211
DR   GEO; GSM886848
DR   GEO; GSM887912
DR   GEO; GSM1669575
DR   IARC_TP53; 21155
DR   LiGeA; CCLE_823
DR   LINCS_LDP; LCL-1365
DR   PharmacoDB; 8MGBA_29_2019
DR   Wikidata; Q54605281
RX   PubMed=9604998;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 20-24 hours (PubMed=9604998); ~100 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for TP53 p.Arg273Cys (c.817C>T) (ClinVar=VCV000043594) (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.1%; East Asian, North=2.53%; East Asian, South=0%; South Asian=2.29%; European, North=61.9%; European, South=33.19% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 12
ST   D5S818: 10,12
ST   D7S820: 11
ST   TH01: 9,9.3
ST   TPOX: 8,10
ST   vWA: 17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 28
//
RX   PubMed=9604998;
RA   Perzelova A., Macikova I., Mraz P., Bizik I., Steno J.;
RT   "Characterization of two new permanent glioma cell lines 8-MG-BA and
RT   42-MG-BA.";
RL   Neoplasma 45:25-29(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//